US-based medical device company Abbott has teamed up with CamDiab and Ypsomed to jointly develop and market an integrated automated insulin delivery (AID) system in Europe.
The new integrated delivery system will combine Abbott’s FreeStyle Libre 3 sensor, CamDiab’s CamAPS FX mobile app, and Ypsomed’s mylife YpsoPump.
It will work to continuously monitor patients’ glucose levels and automatically adjust and deliver the precise dosing of insulin at the right time.
CamDiab is a digital health company that designs, develops, ad markets interoperable CamAPS FX app, which leverages an adaptive, self-learning control algorithm.
When connected to a compatible CGM device and insulin pump, CamAPS FX autonomously computes and guides insulin delivery to ensure appropriate glycaemic control.
CamDiab director Roman Hovorka said: “Our CamAPS FX, already approved in Europe, is a highly adaptive algorithm that when integrated with Abbott’s sensor is being designed to communicate with Ypsomed’s insulin pump to provide the optimal insulin dose, lifting the burden of managing a condition that is relentlessly unpredictable day and night.”
Ypsomed Delivery Systems (YDS) is a Swiss developer and manufacturer of injection and infusion systems for self-medication.
It provides pharmaceutical and biotech companies with pens, autoinjectors, pump systems and software solutions for administering liquid medications.
Ypsomed chief executive officer Simon Michel said: “When combined our mylife YpsoPump with the FreeStyle Libre 3 system and CamAPS FX advanced adaptive hybrid closed-loop app, we will be able to deliver an additional compact and lightweight AID system that is discreet and simple to use.”
Abbott said that its FreeStyle Libre 3 is the world’s smallest and most accurate continuous glucose monitoring sensor that delivers readings every minute.
The new connected, smart wearable solution will create a smart, automated process to deliver insulin based on real-time glucose data.
Abbott diabetes care business senior vice president Jared Watkin said: “Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching and technology leaders.
“We want to deliver new advanced solutions that simplify and make it possible for people to spend less time thinking about diabetes and more time living.”
The partnership aims to complete the development of the AID system by end of this year, with plans to commercialise the system subsequently.
